Jordan Brignac, APRN
Family · Prairieville, LANPI 1528410594
Payments from drug & device makers
Across 268 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$859
- Astellas Pharma US Inc$442
- Abbott$185
- Pfizer$140
- Novo Nordisk$138
- plus $877 from 26 others
What the payments were for
- Food & beverage$3,90798%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 117 | $1,367 |
| GSK | 53 | $859 |
| Astellas Pharma US Inc | 20 | $442 |
| Abbott | 10 | $185 |
| Pfizer | 8 | $140 |
| Novo Nordisk | 9 | $138 |
| Johnson & Johnson | 8 | $118 |
| Jazz Pharmaceuticals Inc. | 4 | $106 |
| Bayer | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Merz North America, Inc. | 1 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Almatica Pharma LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Novartis | 2 | $31 |
| Exact Sciences | 2 | $30 |
| Eisai Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Amgen | 2 | $28 |
| Lilly USA, LLC | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Corium, LLC | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| AstraZeneca | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Merck | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$4,007 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 156 | $198,621 |
| OzempicSemaglutide | 101 | $113,099 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $65,208 |
| JardianceEmpagliflozin | 49 | $55,828 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $47,000 |
| EliquisApixaban | 29 | $34,655 |
| XareltoRivaroxaban | 29 | $26,178 |
| TrulicityDulaglutide | 18 | $19,346 |
| VraylarCariprazine Hcl | 13 | $18,749 |
| LinzessLinaclotide | 13 | $16,939 |
| FarxigaDapagliflozin Propanediol | 25 | $16,697 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $10,351 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,607 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,169 |
| Lisdexamfetamine Dimesylate | 12 | $3,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $27 | $217,967174 claims |
| Novo NordiskOzempic | $138 | $113,099101 claims |
| GSKTrelegy Ellipta | $859 | $65,20894 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $33 | $60,99760 claims |
| AbbVieVraylar, Linzess | $1,367 | $35,68826 claims |
| PfizerEliquis | $140 | $34,65529 claims |
| Johnson & JohnsonXarelto | $118 | $26,17829 claims |
| AstraZenecaFarxiga | $18 | $16,69725 claims |
| Almatica Pharma LLCSertraline Hcl | $35 | $60685 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Prairieville
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.